Metformin: evidence, dosing, safety & interactions
Metformin hydrochloride (1,1-dimethylbiguanide hydrochloride)
This is a well-established, widely prescribed diabetes medicine. Some studies suggest people taking it for diabetes lived slightly longer — but that isn't the same as proof it helps otherwise-healthy people live longer, and more research is needed.
- What it is
- A prescription-only biguanide, approved worldwide for type 2 diabetes, taken off-label by some for its proposed anti-aging effects.
- Evidence
- A large UK observational study found metformin-treated diabetics had longer adjusted survival than matched non-diabetic controls. This is real but confounded data, not a randomized trial, and it was run in diabetics, not the healthy population the longevity claim targets.
- Studied dose
- Typical diabetes dosing is 500–2,000 mg/day. No trial has established a dose specifically for longevity in non-diabetics.
- Safety
- Well characterised for diabetes after decades of use. Main risks are GI side effects, rare lactic acidosis with kidney impairment, and B12 deficiency with long-term use.
What human trials actually show
Randomized, placebo-controlled human trials only. Animal data never appears in this section — it cannot raise a grade, and it is noted separately below.
- 01Diabetes, Obesity and Metabolism2014— All-cause mortality: metformin vs. sulfonylurea vs. non-diabetic controls
- Design
- Retrospective observational cohort study using UK Clinical Practice Research Datalink (CPRD) data
- Dose
- Real-world metformin or sulfonylurea monotherapy dosing, as prescribed in UK primary care
- Duration
- Retrospective cohort, from 2000 onward
78,241 people with type 2 diabetes on metformin monotherapy, 12,222 on sulfonylurea monotherapy, and 90,463 matched people without diabetes; 503,384 total person-years of follow-up
Diabetic patients started on metformin monotherapy had longer adjusted median survival (reference survival time ratio = 1.0) than matched non-diabetic controls, whose adjusted survival was 15% lower (STR=0.85). Diabetic patients on sulfonylurea monotherapy had 38% lower survival (STR=0.62) than the metformin group. This is an observational association: it does not prove metformin causes longer survival, since diabetics and non-diabetics differ in many ways beyond drug exposure, and healthier or more health-engaged patients may be more likely to be prescribed and stay on metformin in the first place.
doi:10.1111/dom.12354
This is the central gap: the finding that motivates interest in metformin for longevity comes from diabetics compared with non-diabetics, in an observational (not randomized) design — meaning confounding factors that differ between people who develop diabetes and people who don't (weight, activity, healthcare engagement, other prescriptions) cannot be ruled out as the real explanation. The trial designed to test metformin directly in healthy, non-diabetic older adults — TAME (Targeting Aging with Metformin) — has been proposed and designed but has not completed or reported results. Until it does, or an equivalent trial does, metformin's longevity case remains a plausible hypothesis built on an association in the wrong population, not a demonstrated effect in the population it is actually being suggested for.
Grade C — early. The longevity case rests on a large but confounded observational comparison in diabetics, not a completed trial in the healthy, non-diabetic population the claim is actually about. The dedicated trial designed to test that (TAME) has not reported results. How we grade evidence.
Side effects & safety
- Common
- Gastrointestinal side effects — nausea, diarrhoea, abdominal discomfort — are the most frequently reported issue, especially when starting or increasing dose, and are well documented across decades of diabetes use.
- Serious but rare
- Lactic acidosis is a rare but serious risk, occurring almost exclusively in the context of significant kidney impairment, severe illness, or other conditions that impair lactate clearance — it is why renal function is checked before and during treatment.
- Long-term use
- Vitamin B12 deficiency is a recognised effect of long-term metformin use, which can go unnoticed without periodic monitoring, especially in older adults.
- The honest caveat
- None of this safety profile is in question — metformin is one of the best-characterised drugs in medicine for diabetes. What is unresolved is whether it does anything protective in people who do not have diabetes, which is a completely different question from whether it is safe.
Interactions with medications
The section most longevity sites skip. If you take prescription medication, read this before anything else on the page.
Published exercise-physiology research has raised concern that metformin can blunt some of the mitochondrial and cardiorespiratory adaptations to structured aerobic and resistance training. If your protocol leans heavily on a training programme for its longevity value, this is a real trade-off to discuss with whoever prescribes it, not a theoretical one.
Metformin is typically held before and after contrast imaging because of the lactic-acidosis risk if kidney function is transiently impaired by the contrast — a standard, well-established precaution.
Heavy alcohol use raises lactic-acidosis risk on metformin and can also mask or worsen low blood sugar. Not a reason to avoid all alcohol, but heavy or binge use is a specific concern.
Because metformin clearance depends on kidney function, anything that reduces renal function raises the lactic-acidosis risk indirectly. Kidney function should be checked periodically, especially if other renally-cleared medications are added.
Long-term use can lower B12 levels. Periodic monitoring, especially in older adults or those with reduced dietary B12 intake, is a reasonable precaution rather than a rare edge case.
Is Metformin legal where you live?
Regulatory status is tracked per market and reviewed on the date shown. Where a compound is not authorised, this site does not link to sellers.
FDA-approved by prescription only for type 2 diabetes. Not approved for longevity or anti-aging use; off-label prescribing for that purpose is a physician's individual decision, not an FDA-sanctioned indication.
Source: US Food and Drug Administration
Licensed by the MHRA by prescription for type 2 diabetes. No licence exists for anti-aging or longevity use.
Source: MHRA
Authorised across the EU by prescription for type 2 diabetes. No EU authorisation exists for longevity or anti-aging use.
Source: European Medicines Agency
Autorisée sur ordonnance pour le diabète de type 2. Aucune autorisation n'existe pour un usage lié à la longévité ou à l'anti-âge.
Source: ANSM / Agence européenne des médicaments
Autorizada con receta para la diabetes tipo 2. No existe autorización para un uso relacionado con la longevidad o el antienvejecimiento.
Source: AEMPS / Agencia Europea de Medicamentos
Verschreibungspflichtig zugelassen zur Behandlung von Typ-2-Diabetes. Für eine Anwendung im Bereich Langlebigkeit oder Anti-Aging besteht keine Zulassung.
Source: BfArM / Europäische Arzneimittel-Agentur
MOHAP's own public advisories on metformin (issued during a 2020 NDMA-impurity review) confirm it is dispensed only against a prescription from a DHA- or DOH-licensed physician, and it is not classified as a controlled substance under UAE Federal Law No. 14 of 1995. No anti-aging or longevity approval exists.
Source: UAE Ministry of Health and Prevention (MOHAP)
Metformin combination products (for example alogliptin/metformin) carry active SFDA registration records as prescription medicines in Saudi Arabia. As in every other market, there is no SFDA approval for any anti-aging or longevity use.
Source: Saudi Food and Drug Authority (SFDA)
La metformina è autorizzata su prescrizione per il diabete di tipo 2 in tutta l'UE; l'autorizzazione vale anche in Italia attraverso le normali procedure di mutuo riconoscimento, senza differenze rilevanti rispetto agli altri Stati membri. Nessuna autorizzazione esiste per un uso legato alla longevità o all'anti-invecchiamento.
Source: Agenzia Italiana del Farmaco (AIFA) / Agenzia europea per i medicinali (EMA)
Metformine is EU-breed op recept goedgekeurd voor de behandeling van diabetes type 2, ook in Nederland, via de gebruikelijke wederzijdse-erkenningsprocedures — geen wezenlijk verschil met andere lidstaten gevonden. Er bestaat nergens een goedkeuring voor gebruik gericht op veroudering of levensduur.
Source: CBG-MEB / Europees Geneesmiddelenbureau (EMA)
A metformina tem registro ativo e consolidado na Anvisa, com diversos genéricos aprovados (incluindo combinações recentes, como dapagliflozina/metformina, aprovada em maio de 2026), sob a Lei dos Genéricos (Lei nº 9.787/1999), disponível apenas com prescrição médica para diabetes tipo 2. Como em qualquer outro mercado, não existe aprovação da Anvisa para uso relacionado a longevidade ou anti-envelhecimento.
Source: Agência Nacional de Vigilância Sanitária (ANVISA)
Dosing & timing
This is the well-established dosing range for type 2 diabetes, typically titrated upward from a lower starting dose to reduce GI side effects.
No trial has determined a dose specifically for anti-aging use in non-diabetics. Off-label prescribing, where it happens, generally borrows from the diabetes dosing range rather than from any dedicated longevity trial data, because no such trial has reported.
Metformin requires a prescription in every market this site covers. There is no over-the-counter or supplement route to it, and using it without medical supervision means no baseline kidney-function check or B12 monitoring.
Cost: Generic metformin itself is inexpensive where it is prescribed for diabetes; the real cost of off-label longevity use is typically the physician relationship and monitoring (kidney function, B12) needed to use it responsibly outside its approved indication.
Questions people actually ask
Has the TAME trial for metformin and aging been completed?
No. TAME (Targeting Aging with Metformin) is a trial proposed and designed specifically to test metformin's effect on aging-related outcomes in healthy, non-diabetic older adults. As of the most recent available information, it has not completed enrollment and reported results. Any claim describing TAME's findings is describing something that has not happened yet.
If diabetics on metformin outlive non-diabetics, doesn't that prove it works for longevity?
It is a striking observational finding, not proof. People who develop type 2 diabetes and are prescribed metformin differ from the general non-diabetic population in ways beyond the drug itself — weight, activity level, engagement with healthcare, and other prescriptions all differ. The 2014 UK study behind this finding was observational, and its authors describe it as supporting metformin's position as first-line diabetes therapy — not as proof of an anti-aging effect in people without diabetes.
Is metformin approved for anti-aging use?
No, anywhere. Metformin is approved worldwide for type 2 diabetes and is prescription-only. Any use aimed at longevity or healthy aging is off-label, meaning a physician can choose to prescribe it for that reason in some places, but no regulator has evaluated or approved it for that purpose.
Does metformin interfere with exercise training?
There is a specific, published concern that metformin can blunt some of the mitochondrial and fitness adaptations that come from structured aerobic and resistance training. If exercise is a central part of your longevity approach, this interaction is worth discussing directly with whoever prescribes the drug.
What are metformin's main risks?
Gastrointestinal side effects are the most common complaint. The more serious but rare risk is lactic acidosis, almost always tied to significant kidney impairment. Long-term use can also lower vitamin B12 levels. None of this is unusual or poorly understood — metformin has one of the longest and best-documented safety records of any diabetes drug.